文献速递胸部肿瘤

聚乙二醇精氨酸酶联合一线化疗治疗非上皮样胸膜间皮瘤患者:ATOMIC-Meso随机临床试验

Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2024-01-01

ATOMIC-Meso是一项在5个国家43个中心开展的2-3期双盲随机临床试验,纳入249例化疗初治的非上皮样胸膜间皮瘤患者,比较标准化疗联合聚乙二醇精氨酸酶(pegargiminase)或安慰剂。结果显示,聚乙二醇精氨酸酶组中位总生存期为9.3个月,安慰剂组为7.7个月(HR 0.71,95%CI 0.55-0.93,P=0.02);中位无进展生存期分别为6.2个月和5.6个月(HR 0.65,95%CI 0.46-0.90,P=0.02)。聚乙二醇精氨酸酶组3-4级不良事件发生率为28.8%,安慰剂组为16.9%。

要点

  • 聚乙二醇精氨酸酶联合化疗较安慰剂联合化疗延长非上皮样胸膜间皮瘤患者总生存期(9.3 vs 7.7个月,HR 0.71)。
  • 聚乙二醇精氨酸酶组3-4级不良事件发生率为28.8%,安慰剂组为16.9%。
  • 聚乙二醇精氨酸酶组药物过敏反应3例(2.4%),皮肤反应2例(1.6%),安慰剂组均无。

核心结论

  • 在非上皮样胸膜间皮瘤患者中,聚乙二醇精氨酸酶联合化疗较标准化疗延长生存期,且安全性可控。
  • 基于聚乙二醇精氨酸酶的抗代谢策略在肿瘤学中值得更广泛的临床测试。

研究设计与样本

  • 2-3期双盲随机临床试验,在5个国家43个中心开展,纳入249例化疗初治的非上皮样胸膜间皮瘤患者。
  • 患者按1:1随机分配接受每周肌内注射聚乙二醇精氨酸酶(36.8 mg/m2)或安慰剂,所有患者每3周静脉接受培美曲塞(500 mg/m2)和铂类(顺铂75 mg/m2或卡铂AUC 5)化疗,最多6个周期。
  • 聚乙二醇精氨酸酶或安慰剂持续至疾病进展、毒性或24个月。
  • 研究纳入时间为2017年8月1日至2021年8月15日,末次随访时间为2022年8月15日,数据分析时间为2018年3月至2023年6月。

主要发现

  • 聚乙二醇精氨酸酶联合化疗组中位总生存期为9.3个月(95%CI 7.9-11.8),安慰剂联合化疗组为7.7个月(95%CI 6.1-9.5),死亡风险比HR 0.71(95%CI 0.55-0.93,P=0.02)。
  • 聚乙二醇精氨酸酶联合化疗组中位无进展生存期为6.2个月(95%CI 5.8-7.4),安慰剂联合化疗组为5.6个月(95%CI 4.1-5.9),HR 0.65(95%CI 0.46-0.90,P=0.02)。
  • 聚乙二醇精氨酸酶组3-4级不良事件发生36例(28.8%),安慰剂组21例(16.9%)。
  • 聚乙二醇精氨酸酶组药物过敏反应3例(2.4%),皮肤反应2例(1.6%),安慰剂组均无。
  • 研究后治疗率两组相当:聚乙二醇精氨酸酶组57例(45.6%),安慰剂组58例(46.8%)。

临床怎么用

  • 作者认为,基于聚乙二醇精氨酸酶的抗代谢策略在间皮瘤中值得更广泛的肿瘤学临床测试。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Arginine deprivation using ADI-PEG20 (pegargiminase) combined with chemotherapy is untested in a randomized study among patients with cancer. ATOMIC-Meso (ADI-PEG20 Targeting of Malignancies Induces Cytotoxicity-Mesothelioma) is a pivotal trial comparing standard first-line chemotherapy plus pegargiminase or placebo in patients with nonepithelioid pleural mesothelioma. OBJECTIVE: To determine the effect of pegargiminase-based chemotherapy on survival in nonepithelioid pleural mesothelioma, an arginine-auxotrophic tumor. DESIGN, SETTING, AND PARTICIPANTS: This was a phase 2-3, double-blind randomized clinical trial conducted at 43 centers in 5 countries that included patients with chemotherapy-naive nonepithelioid pleural mesothelioma from August 1, 2017, to August 15, 2021, with at least 12 months' follow-up. Final follow-up was on August 15, 2022. Data analysis was performed from March 2018 to June 2023. INTERVENTION: Patients were randomly assigned (1:1) to receive weekly intramuscular pegargiminase (36.8 mg/m2) or placebo. All patients received intravenous pemetrexed (500 mg/m2) and platinum (75-mg/m2 cisplatin or carboplatin area under the curve 5) chemotherapy every 3 weeks up to 6 cycles. Pegargiminase or placebo was continued until progression, toxicity, or 24 months. MAIN OUTCOMES AND MEASURES: The primary end point was overall survival, and secondary end points were progression-free survival and safety. Response rate by blinded independent central review was assessed in the phase 2 portion only. RESULTS: Among 249 randomized patients (mean [SD] age, 69.5 [7.9] years; 43 female individuals [17.3%] and 206 male individuals [82.7%]), all were included in the analysis. The median overall survival was 9.3 months (95% CI, 7.9-11.8 months) with pegargiminase-chemotherapy as compared with 7.7 months (95% CI, 6.1-9.5 months) with placebo-chemotherapy (hazard ratio [HR] for death, 0.71; 95% CI, 0.55-0.93; P = .02). The median progression-free survival was 6.2 months (95% CI, 5.8-7.4 months) with pegargiminase-chemotherapy as compared with 5.6 months (95% CI, 4.1-5.9 months) with placebo-chemotherapy (HR, 0.65; 95% CI, 0.46-0.90; P = .02). Grade 3 to 4 adverse events with pegargiminase occurred in 36 patients (28.8%) and with placebo in 21 patients (16.9%); drug hypersensitivity and skin reactions occurred in the experimental arm in 3 patients (2.4%) and 2 patients (1.6%), respectively, and none in the placebo arm. Rates of poststudy treatments were comparable in both arms (57 patients [45.6%] with pegargiminase vs 58 patients [46.8%] with placebo). CONCLUSIONS AND RELEVANCE: In this randomized clinical trial of arginine depletion with pegargiminase plus chemotherapy, survival was extended beyond standard chemotherapy with a favorable safety profile in patients with nonepithelioid pleural mesothelioma. Pegargiminase-based chemotherapy as a novel antimetabolite strategy for mesothelioma validates wider clinical testing in oncology. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02709512.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Szlosarek PW, Creelan BC, Sarkodie T, et al. Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial. JAMA Oncol. 2024. PMID: 38358753. doi:10.1001/jamaoncol.2023.6789

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。